Journal Watch · Nature Communications · 2026

RAGE mediates LPS-induced inflammatory pain in human skin - a double-blind, randomised, placebo-controlled full crossover study.

The human lipopolysaccharide skin inflammation model depends largely on the Receptor for Advanced Glycation End-products, highlighting its potential as a target in inflammation.

Resch FJ, Pramhas S, Jilma B et al.Nature Communications3 min readPharma relevance 50/100

DOI: 10.1038/s41467-026-76771-2PMID: 42830319Study type: randomised / controlled clinical trial

TL;DR

The human lipopolysaccharide skin inflammation model depends largely on the Receptor for Advanced Glycation End-products, highlighting its potential as a target in inflammation.

Key findings

  • In contrast, the Toll-like receptor 4 antagonist resatorvid has no effect on these readouts.
  • In both naïve and inflamed skin, the TRPV1 antagonist BCTC inhibits the majority of acid-induced pain.
  • Lipopolysaccharide-induced inflammation causes a substantial shift in the pH sensitivity of pain, suggesting that even mild tissue acidification contributes to inflammatory pain.
  • The human lipopolysaccharide skin inflammation model depends largely on the Receptor for Advanced Glycation End-products, highlighting its potential as a target in inflammation.

Numbers at a glance (from the abstract)

87%55%40%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

The double-blind, randomised, placebo-controlled full crossover main study (NCT07092215) included 40 healthy subjects and investigated the role of the Receptor for Advanced Glycation End-products. The primary hypothesis was: 'The blood flow is different in lipopolysaccharide-injected skin spots compared to lipopolysaccharide-injected skin spots where azeliragon is co-injected'. The two secondary hypotheses were: 'Acid-induced pain is different in lipopolysaccharide-injected skin spots compared to lipopolysaccharide-injected skin spots where azeliragon is co-injected' and 'Mechanical pinch-induced pain is different in lipopolysaccharide-injected skin spots compared to lipopolysaccharide-injected skin spots where azeliragon is co-injected'. Co-injection of the respective antagonist azeliragon largely reduces lipopolysaccharide-induced hyperaemia (-87%) and significantly attenuates hypersensitivity to mechanical (-55%) and increasingly acidic stimuli (-40%).

Full abstract (original)

Background: Inflammatory pain is a major clinical challenge, yet appropriate human models mimicking local infection are lacking. We established a human pain model based on intradermal administration of lipopolysaccharide, a component of Gram-negative bacteria, and investigated the time course and underlying molecular mechanisms of inflammatory pain hypersensitivity. A placebo-controlled pilot study with 12 healthy subjects showed that intradermal lipopolysaccharide injection induces hyperaemia peaking at 4.5 h and mechanical hypersensitivity peaking at 6 h. Hypersensitivity to increasingly acidic injections and mechanical pinch lasts longer than hyperaemia.

What they did: The double-blind, randomised, placebo-controlled full crossover main study (NCT07092215) included 40 healthy subjects and investigated the role of the Receptor for Advanced Glycation End-products. The primary hypothesis was: 'The blood flow is different in lipopolysaccharide-injected skin spots compared to lipopolysaccharide-injected skin spots where azeliragon is co-injected'. The two secondary hypotheses were: 'Acid-induced pain is different in lipopolysaccharide-injected skin spots compared to lipopolysaccharide-injected skin spots where azeliragon is co-injected' and 'Mechanical pinch-induced pain is different in lipopolysaccharide-injected skin spots compared to lipopolysaccharide-injected skin spots where azeliragon is co-injected'. Co-injection of the respective antagonist azeliragon largely reduces lipopolysaccharide-induced hyperaemia (-87%) and significantly attenuates hypersensitivity to mechanical (-55%) and increasingly acidic stimuli (-40%).

Results & conclusions: In contrast, the Toll-like receptor 4 antagonist resatorvid has no effect on these readouts. In both naïve and inflamed skin, the TRPV1 antagonist BCTC inhibits the majority of acid-induced pain. Lipopolysaccharide-induced inflammation causes a substantial shift in the pH sensitivity of pain, suggesting that even mild tissue acidification contributes to inflammatory pain. The human lipopolysaccharide skin inflammation model depends largely on the Receptor for Advanced Glycation End-products, highlighting its potential as a target in inflammation.

Abstract © the authors / Nature Communications (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41467-026-76771-2 · PubMed 42830319.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Nature Communications study find?

The human lipopolysaccharide skin inflammation model depends largely on the Receptor for Advanced Glycation End-products, highlighting its potential as a target in inflammation.

What type of study is this?

It is a randomised / controlled clinical trial, published in Nature Communications in 2026. The double-blind, randomised, placebo-controlled full crossover main study (NCT07092215) included 40 healthy subjects and investigated the role of the Receptor for Advanced Glycation End-products.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41467-026-76771-2. PubMed ID: 42830319. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Resch FJ, Pramhas S, Jilma B et al.. RAGE mediates LPS-induced inflammatory pain in human skin - a double-blind, randomised, placebo-controlled full crossover study.. Nature Communications (2026). DOI: 10.1038/s41467-026-76771-2.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/rage-mediates-lps-induced-inflammatory-pain-in-human-skin-a-double-blind-767712/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides